-
1دورية أكاديمية
المؤلفون: van den Bent, Martin J, Baumert, Brigitta, Erridge, Sara C, Vogelbaum, Michael A, Nowak, Anna K, Sanson, Marc, Brandes, Alba Ariela, Clement, Paul M, Baurain, Jean Francais, Mason, Warren P, Wheeler, Helen, Chinot, Olivier L, Gill, Sanjeev, Griffin, Matthew, Brachman, David G, Taal, Walter, Rudà, Roberta, Weller, Michael, McBain, Catherine, Reijneveld, Jaap, Enting, Roelien H, Weber, Damien C, Lesimple, Thierry, Clenton, Susan, Gijtenbeek, Anja, Pascoe, Sarah, Herrlinger, Ulrich, Hau, Peter, Dhermain, Frederic, van Heuvel, Irene, Stupp, Roger, Aldape, Ken, Jenkins, Robert B, Dubbink, Hendrikus Jan, Dinjens, Winand N M, Wesseling, Pieter, Nuyens, Sarah, Golfinopoulos, Vassilis, Gorlia, Thierry, Wick, Wolfgang, Kros, Johan M
المصدر: van den Bent , M J , Baumert , B , Erridge , S C , Vogelbaum , M A , Nowak , A K , Sanson , M , Brandes , A A , Clement , P M , Baurain , J F , Mason , W P , Wheeler , H , Chinot , O L , Gill , S , Griffin , M , Brachman , D G , Taal , W , Rudà , R , Weller , M , McBain , C , Reijneveld , J , Enting , R H , Weber , ....
مصطلحات موضوعية: BRAIN-TUMOR GROUP, LOW-GRADE GLIOMA, EUROPEAN ORGANIZATION, OLIGODENDROGLIAL TUMORS, IDH2 MUTATIONS, III TRIAL, PROCARBAZINE, VINCRISTINE, GLIOBLASTOMA, CHEMOTHERAPY
الإتاحة: https://doi.org/10.1016/S0140-6736Test(17)31442-3
https://hdl.handle.net/11370/e0a08e12-2ea9-4561-be22-0764dde6546eTest
https://research.rug.nl/en/publications/e0a08e12-2ea9-4561-be22-0764dde6546eTest
https://www.zora.uzh.ch/id/eprint/141071/1/catnon_manuscript_lancetv_3rd_revision_final.pdfTest -
2
المؤلفون: Anja Gijtenbeek, Vassilis Golfinopoulos, Michael Weller, Sarah Pascoe, Roger Stupp, Sara Erridge, Irene van Heuvel, Marc Sanson, Winand N.M. Dinjens, Hendrikus J. Dubbink, Warren P. Mason, David Brachman, Martin J. van den Bent, Robert B. Jenkins, Peter Hau, Wolfgang Wick, Thierry Lesimple, Susan Clenton, Matthew E. Griffin, Jean Francais Baurain, Brigitta G. Baumert, Sanjeev Gill, Roelien H. Enting, Walter Taal, Damien C. Weber, Kenneth Aldape, Pieter Wesseling, Roberta Rudà, Catherine McBain, Helen Wheeler, Sarah Nuyens, Johan M. Kros, Anna K. Nowak, Paul Clement, Frédéric Dhermain, Thierry Gorlia, Ulrich Herrlinger, Olivier Chinot, Jaap C. Reijneveld, Alba A. Brandes, Michael A. Vogelbaum
المساهمون: CCA - Cancer Treatment and quality of life, Neurology, Amsterdam Neuroscience - Systems & Network Neuroscience, Amsterdam Neuroscience - Brain Imaging, Pathology, Erasmus MC other, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Radiotherapie
المصدر: The Lancet, 390(10103), 1645-1653. Elsevier Limited
The Lancet, 390(10103), 1645-1653. ELSEVIER SCIENCE INC
van den Bent, M J, Baumert, B, Erridge, S C, Vogelbaum, M A, Nowak, A K, Sanson, M, Brandes, A A, Clement, P M, Baurain, J F, Mason, W P, Wheeler, H, Chinot, O L, Gill, S, Griffin, M, Brachman, D G, Taal, W, Rudà, R, Weller, M, McBain, C, Reijneveld, J, Enting, R H, Weber, D C, Lesimple, T, Clenton, S, Gijtenbeek, A, Pascoe, S, Herrlinger, U, Hau, P, Dhermain, F, van Heuvel, I, Stupp, R, Aldape, K, Jenkins, R B, Dubbink, H J, Dinjens, W N M, Wesseling, P, Nuyens, S, Golfinopoulos, V, Gorlia, T, Wick, W & Kros, J M 2017, ' Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma : A phase 3, randomised, open-label intergroup study ', The Lancet, vol. 390, no. 10103, pp. 1645-1653 . https://doi.org/10.1016/S0140-6736Test(17)31442-3
Lancet, 390(10103), 1645-1653. Elsevier Limited
The Lancet (London), 390, 1645-1653
Lancet (UK), 390(10103), 1645-1653. Elsevier Ltd.
Lancet, 390(10103), 1645-1653. Elsevier Science
The Lancet (London), 390, 10103, pp. 1645-1653مصطلحات موضوعية: Oncology, medicine.medical_specialty, medicine.medical_treatment, PROCARBAZINE, IDH2 MUTATIONS, Other Research Donders Center for Medical Neuroscience [Radboudumc 0], GLIOBLASTOMA, OLIGODENDROGLIAL TUMORS, Procarbazine, Article, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, EUROPEAN ORGANIZATION, Internal medicine, medicine, BRAIN-TUMOR GROUP, VINCRISTINE, 610 Medicine & health, Chemotherapy, Temozolomide, Intention-to-treat analysis, III TRIAL, Performance status, business.industry, Hazard ratio, LOW-GRADE GLIOMA, General Medicine, CHEMOTHERAPY, Interim analysis, Surgery, Radiation therapy, 030220 oncology & carcinogenesis, business, 030217 neurology & neurosurgery, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f496146f8de3c40bcefcd6b7e1263417Test
https://doi.org/10.1016/s0140-6736Test(17)31442-3 -
3دورية أكاديمية
المؤلفون: van den Bent, Martin J., Erdem-Eraslan, Lale, Idbaih, Ahmed, de Rooi, Johan, Eilers, Paul H. C., Spliet, Wim G. M., den Dunnen, Wilfred F. A., Tijssen, Cees, Wesseling, Pieter, Smitt, Peter A. E. Sillevis, Kros, Johan M., Gorlia, Thierry, French, Pim J.
المصدر: van den Bent , M J , Erdem-Eraslan , L , Idbaih , A , de Rooi , J , Eilers , P H C , Spliet , W G M , den Dunnen , W F A , Tijssen , C , Wesseling , P , Smitt , P A E S , Kros , J M , Gorlia , T & French , P J 2013 , ' MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951 ' , Clinical Cancer Research , vol. 19 ....
مصطلحات موضوعية: PHASE-III TRIAL, BRAIN-TUMOR GROUP, ADJUVANT PROCARBAZINE, VINCRISTINE CHEMOTHERAPY, EUROPEAN ORGANIZATION, MGMT METHYLATION, IDH2 MUTATIONS, GLIOBLASTOMA, RADIOTHERAPY, TEMOZOLOMIDE
الإتاحة: https://doi.org/10.1158/1078-0432.CCR-13-1157Test
https://hdl.handle.net/11370/3b92f512-4e69-4779-b16c-9d132bff582aTest
https://research.rug.nl/en/publications/3b92f512-4e69-4779-b16c-9d132bff582aTest -
4
المؤلفون: Martin J. van den Bent, Johan J. de Rooi, Lale Erdem-Eraslan, Wim G.M. Spliet, Peter A. E. Sillevis Smitt, Pieter Wesseling, Cees C. Tijssen, Paul H. C. Eilers, Ahmed Idbaih, Pim J. French, Thierry Gorlia, Johan M. Kros, Wilfred F. A. den Dunnen
المساهمون: Neurology, Epidemiology, Pathology, Molecular Neuroscience and Ageing Research (MOLAR), CCA - Disease profiling
المصدر: Clinical Cancer Research, 19(19), 5513-5522. American Association for Cancer Research Inc.
Clinical Cancer Research, 19(19), 5513-5522. AMER ASSOC CANCER RESEARCH
Clinical Cancer Research, 19, 5513-22
Clinical Cancer Research, 19, 19, pp. 5513-22
van den Bent, M J, Erdem-Eraslan, L, Idbaih, A, de Rooi, J, Eilers, P H C, Spliet, W G M, den Dunnen, W F A, Tijssen, C, Wesseling, P, Sillevis Smitt, P A E, Kros, J M, Gorlia, T & French, P J 2013, ' MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951 ', Clinical Cancer Research, vol. 19, no. 19, pp. 5513-5522 . https://doi.org/10.1158/1078-0432.CCR-13-1157Testمصطلحات موضوعية: Oncology, Male, Cancer Research, Pathology, IDH2 MUTATIONS, Procarbazine, MGMT METHYLATION, EUROPEAN ORGANIZATION, Lomustine, Antineoplastic Combined Chemotherapy Protocols, Cluster Analysis, BRAIN-TUMOR GROUP, Promoter Regions, Genetic, DNA Modification Methylases, VINCRISTINE CHEMOTHERAPY, Univariate analysis, Predictive marker, TEMOZOLOMIDE, PHASE-III TRIAL, Methylation, Prognosis, Translational research Tissue engineering and pathology [ONCOL 3], Phenotype, Treatment Outcome, CpG site, Vincristine, DNA methylation, Female, medicine.drug, RADIOTHERAPY, medicine.medical_specialty, ADJUVANT PROCARBAZINE, Oligodendroglioma, GLIOBLASTOMA, Internal medicine, medicine, Humans, neoplasms, Temozolomide, business.industry, Gene Expression Profiling, Tumor Suppressor Proteins, DNA Methylation, digestive system diseases, DNA Repair Enzymes, CpG Islands, business, Biomarkers
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7561df3c041dff6c11a84f19a2023b64Test
https://pure.eur.nl/en/publications/74064b40-7988-40ea-8647-0197c09d6b56Test